4D Molecular Therapeutics, Inc.'s revenue has grown 243% a year over three years, and grown 32% a year over five. Revenue growth, 3-year annual rate: +243% (Biotechnology median +21%). Revenue growth, 5-year rate: +32%, growth has picked up over the last three years. Years of annual history on file: 7, FY2019 to FY2025, as filed.

FDMT4D Molecular Therapeutics, Inc.

Healthcare

$10.78+2.5% 1Y

$10.78

$7.1952 weeks$16.74

Is it growing?

Good

Growing: revenue growing +278712% year on year and operating margin widening (+2005765.3 points).

2 good, 1 without data

Revenue trend+278712% in a year

Trailing-twelve-month revenue vs a year earlier, from the company's own filings. Five-year pace: +32% a year.

Margin direction+2005765.3 points operating

Trailing-twelve-month operating margin, -18104.8% now against -2023870.1% a year earlier.

All from SEC EDGAR, as of Jun 30, 2026.

Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.

Is FDMT growing?

4D Molecular Therapeutics, Inc.'s revenue has grown 243% a year over three years, and grown 32% a year over five.

+243%

Revenue growth, 3-year annual rate · Biotechnology median +21% · compounding fast · compounded from trailing twelve-month revenue

Revenue growth, 5-year rate: +32%
Revenue growth, 5-year rate · +243% over three · growth has picked up over the last three years
Years of annual history on file: 7
Years of annual history on file · FY2019 to FY2025, as filed

Details›